Literature DB >> 11447282

Antibodies with infinite affinity.

A J Chmura1, M S Orton, C F Meares.   

Abstract

Here we report an approach to the design and production of antibody/ligand pairs, to achieve functional affinity far greater than avidin/biotin. Using fundamental chemical principles, we have developed antibody/ligand pairs that retain the binding specificity of the antibody, but do not dissociate. Choosing a structurally characterized antibody/ligand pair as an example, we engineered complementary reactive groups in the antibody binding pocket and the ligand, so that they would be in close proximity in the antibody/ligand complex. Cross-reactions with other molecules in the medium are averted because of the low reactivity of these groups; however, in the antibody/ligand complex the effective local concentrations of the complementary reactive groups are very large, allowing a covalent reaction to link the two together. By eliminating the dissociation of the ligand from the antibody, we have made the affinity functionally infinite. This chemical manipulation of affinity is applicable to other biological binding pairs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447282      PMCID: PMC37461          DOI: 10.1073/pnas.151260298

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

Review 1.  Synthetic haptens as probes of antibody response and immunorecognition.

Authors:  K Shreder
Journal:  Methods       Date:  2000-03       Impact factor: 3.608

2.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction.

Authors:  W Ito; H Ishiguro; Y Kurosawa
Journal:  Gene       Date:  1991-06-15       Impact factor: 3.688

4.  A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin.

Authors:  J Rao; J Lahiri; L Isaacs; R M Weis; G M Whitesides
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

5.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

Authors:  Y Chen; C Wiesmann; G Fuh; B Li; H W Christinger; P McKay; A M de Vos; H B Lowman
Journal:  J Mol Biol       Date:  1999-11-05       Impact factor: 5.469

6.  How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate.

Authors:  R A Love; J E Villafranca; R M Aust; K K Nakamura; R A Jue; J G Major; R Radhakrishnan; W F Butler
Journal:  Biochemistry       Date:  1993-10-19       Impact factor: 3.162

7.  Construction of chimeric molecules by a two-step recombinant PCR method.

Authors:  G Pont-Kingdon
Journal:  Biotechniques       Date:  1994-06       Impact factor: 1.993

8.  Kinetics of the dissociation of indium-(p-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogues from the monoclonal anti-hapten antibody CHA255.

Authors:  D L Meyer; M Fineman; B W Unger; J M Frincke
Journal:  Bioconjug Chem       Date:  1990 Jul-Aug       Impact factor: 4.774

9.  Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions.

Authors:  C F Meares; M J McCall; D T Reardan; D A Goodwin; C I Diamanti; M McTigue
Journal:  Anal Biochem       Date:  1984-10       Impact factor: 3.365

10.  Antibodies against metal chelates.

Authors:  D T Reardan; C F Meares; D A Goodwin; M McTigue; G S David; M R Stone; J P Leung; R M Bartholomew; J M Frincke
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

View more
  28 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation.

Authors:  Bernadette V Marquez; Heather E Beck; Tolulope A Aweda; Brett Phinney; Cynthia Holsclaw; William Jewell; Diana Tran; Jeffrey J Day; Malalage N Peiris; Charles Nwosu; Carlito Lebrilla; Claude F Meares
Journal:  Bioconjug Chem       Date:  2012-05-04       Impact factor: 4.774

3.  New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation.

Authors:  Tolulope A Aweda; Vahid Eskandari; David L Kukis; David L Boucher; Bernadette V Marquez; Heather E Beck; Gregory S Mitchell; Simon R Cherry; Claude F Meares
Journal:  Bioconjug Chem       Date:  2011-07-22       Impact factor: 4.774

Review 4.  The chemistry of irreversible capture.

Authors:  Claude F Meares
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

5.  Electrophilic affibodies forming covalent bonds to protein targets.

Authors:  Lotta Holm; Paul Moody; Mark Howarth
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

Review 6.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 7.  Whither Radioimmunotherapy: To Be or Not To Be?

Authors:  Damian J Green; Oliver W Press
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

Review 8.  Targeting allosteric disulphide bonds in cancer.

Authors:  Philip J Hogg
Journal:  Nat Rev Cancer       Date:  2013-05-10       Impact factor: 60.716

Review 9.  Chemically programmed antibodies.

Authors:  Christoph Rader
Journal:  Trends Biotechnol       Date:  2014-03-11       Impact factor: 19.536

10.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins.

Authors:  Adam J T Smith; Xiyun Zhang; Andrew G Leach; K N Houk
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.